Cargando…

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers

Mobocertinib (TAK‐788) is an investigational oral tyrosine kinase inhibitor targeting epidermal growth factor receptor and human epidermal growth factor 2. A phase 1 open‐label, 2‐period, fixed‐sequence, 2‐part study (NCT03928327) characterized effects of a strong CYP3A4 inhibitor (itraconazole) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Steven, Jin, Shu, Griffin, Celina, Feng, Zhongling, Lin, Jianchang, Venkatakrishnan, Karthik, Gupta, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453750/ https://www.ncbi.nlm.nih.gov/pubmed/34145979 http://dx.doi.org/10.1002/cpdd.967

Ejemplares similares

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
por: Zhang, Steven, et al.
Publicado: (2021)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
por: Garcia Campelo, Maria Rosario, et al.
Publicado: (2022)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
por: Li, Chao, et al.
Publicado: (2022)

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
por: Pithavala, Y. K., et al.
Publicado: (2009)

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
por: Mu, Song, et al.
Publicado: (2019)

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development
por: Hanley, Michael J., et al.
Publicado: (2021)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
por: Riddell, Kylie, et al.
Publicado: (2020)

Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers
por: Lohela, Terhi J., et al.
Publicado: (2020)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study
por: Gupta, Neeraj, et al.
Publicado: (2022)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis
por: Dhoot, Dhiraj, et al.
Publicado: (2023)

A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors
por: Zhu, Zhongling, et al.
Publicado: (2013)

788 Upper Extremity and Lower Extremity Net Devices for Use after Application of Cultured Epidermal Autograft
por: Hayes, Callie J, et al.
Publicado: (2022)

Effect of Itraconazole on the Pharmacokinetics of Diclofenac in Beagle Dogs
por: Al-Jenoobi, Fahad I.
Publicado: (2010)

Clinical Utility of Mobocertinib in the Treatment of NSCLC – Patient Selection and Reported Outcomes
por: Arnold, Abram, et al.
Publicado: (2023)

Posters P788 - P999
Publicado: (2005)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

Pharmacokinetics of Oral Taurine in Healthy Volunteers
por: Ghandforoush-Sattari, Mohammadreza, et al.
Publicado: (2010)

Pharmacokinetics of chloroquine and primaquine in healthy volunteers
por: Daher, André, et al.
Publicado: (2022)

Pharmacokinetics of intranasal amiloride in healthy volunteers
por: Yellepeddi, Venkata K., et al.
Publicado: (2023)

Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator‐Formulated Itraconazole Capsules and Solution in Healthy Dogs
por: Hasbach, A.E., et al.
Publicado: (2017)

Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open‐label, phase I study in healthy subjects
por: Tachibana, Masaya, et al.
Publicado: (2023)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)

Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
por: Andersen, Lars P. H., et al.
Publicado: (2016)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tkiafc4lvbk0aoi34c2nonqpls